Evidence map›Paper›PMID 31150678›Full record

ArticleAntiviral research2019

The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.

Youri Lee, Eun-Ju Ko, Ki-Hye Kim, Young-Tae Lee, Hye Suk Hwang, Yu-Jin Jung, Subbiah Jeeva, Young-Man Kwon, Baik Lin Seong, Sang Moo Kang

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Youri LeeCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Eun-Ju KoCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA; Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ki-Hye KimCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Young-Tae LeeCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Hye Suk HwangCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA; Department of Microbiology, Chonnam National University, Hwasun-gun, Jeonnam, Republic of Korea.
Yu-Jin JungCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Subbiah JeevaCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Young-Man KwonCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Baik Lin SeongInstitute of Life Science and Biotechnology, Yonsei University, Seodaemun-Gu, Seoul, Republic of Korea.
Sang Moo KangCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA. Electronic address: skang24@gsu.edu.
Georgia State University · USNational Institutes of Health · USYonsei University · KR

Funding

Influenza vaccines inducing broadly cross protective immunityR01AI093772 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2011 to 2020
$4.2M
VLP Vaccine TechnologyR01AI105170 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2013 to 2017
$3.7M
New RSV Vaccines with Improved Safety and EfficacyR41AI134132 · NIAID · ADVAC, LLC · PI KANG, SANG-MOO · 2018 to 2018
$225k
NIAID NIH HHS R01 AI093772NIAID NIH HHS R01 AI105170NIAID NIH HHS R41 AI134132
6 · The paper itself

Abstract

Clinical trials with alum-adjuvanted formalin-inactivated human respiratory syncytial virus (FI-RSV) vaccine failed in children due to vaccine-enhanced disease upon RSV infection. In this study, we found that inactivated, detergent-split RSV vaccine (Split) displayed higher reactivity against neutralizing antibodies in vitro and less histopathology in primed adult mice after challenge, compared to FI-RSV. The immunogenicity and efficacy of FI-RSV and Split RSV vaccine were further determined in 2 weeks old mice after a single dose in the absence or presence of monophosphoryl lipid A (MPL) + CpG combination adjuvant. Split RSV with MPL + CpG adjuvant was effective in increasing T helper type 1 (Th1) immune responses and IgG2a isotype antibodies, neutralizing activity, and lung viral clearance as well as modulating immune responses to prevent pulmonary histopathology after RSV vaccination and challenge. This study demonstrates the efficacy of Split RSV as an effective vaccine candidate.

Indexed as

Adjuvants, ImmunologicAlum CompoundsAnimalsAntibodies, NeutralizingCell LineHumansImmunoglobulin GLipid ALungMiceMice, Inbred BALB COligodeoxyribonucleotidesRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesTh1 CellsAdjuvants, ImmunologicAlum Compoundsaluminum sulfateAntibodies, NeutralizingImmunoglobulin GLipid Amonophosphoryl lipid AOligodeoxyribonucleotidesRespiratory Syncytial Virus VaccinesVaccines, InactivatedAdjuvantCpGEnhanced diseaseFI-RSVMPLRSVSplit RSV

Identifiers

PMID31150678
PMCPMC6620154
OpenAlexW2946896355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.